Rituximab-induced Cytokine storm in the absence of overt lymphoproliferative disease

Journal of Pediatric Hematology/Oncology

Volumn 38, Issue 1, 2016, Pages e29-e31

  Williams, Mark ^a   Khalid, Tasneem ^a   Hughes, Stephen ^a   Bonney, Denise ^a   Wynn, Robert ^a  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Cytokine release syndrome; Cytokine storm; Rituximab

Indexed keywords

CYTOKINE; IMMUNOLOGIC FACTOR; RITUXIMAB;

BLOOD; BONE MARROW TRANSPLANTATION; CASE REPORT; CHILD; COMORBIDITY; EPILEPSY; EPSTEIN-BARR VIRUS INFECTIONS; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

BONE MARROW TRANSPLANTATION; CHILD; COMORBIDITY; CYTOKINES; EPILEPSY; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RITUXIMAB;

EID: 84952862601     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000485     Document Type: Article

References (22)

1. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med. 2004;55:477-503.
2. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115-123.
3. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007;11:37-42.
4. Kunkel L, Wong A, Maneatis T, et al. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. Semin Oncol. 2000;27:53-61.
5. Kulkarni HS, Kasi PM. Rituximab and cytokine release syndrome. Case Rep Oncol. 2012;5:134-141.
6. Seifert G, Reindl T, Lobitz S, et al. Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature. Haematologica. 2006;91:69-71.
7. Lim LC, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol. 1999;17:1962-1963.
8. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217-2224.
9. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17:791-795.
10. Wu SJ, Chou WC, Ko BS, et al. Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma. Haematologica. 2007;92:141-142.
11. Shetty S, Ahmed AR. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity. 2013;46:487-496.
12. Brown BA, Torabi M. Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre. Drug Saf. 2011;34:117-123.
13. Conti F, Ceccarelli F, Perricone C, et al. Rituximab infusionrelated adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1148-1152.
14. Covelli M, Sarzi-Puttini P, Atzeni F, et al. Safety of rituximab in rheumatoid arthritis. Reumatismo. 2010;62:101-106.
15. Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2014;8:87-100.
16. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83:142-150.
17. Caraballo RH, Reyes G, Avaria MF, et al. Febrile infectionrelated epilepsy syndrome: a study of 12 patients. Seizure. 2013;22:553-559.
18. Takanashi J, Oba H, Barkovich AJ, et al. Diffusion MRI abnormalities after prolonged febrile seizures with encephalopathy. Neurology. 2006;66:1304-1309; discussion 291.
19. Bugelski PJ, Achuthanandam R, Capocasale RJ, et al. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol. 2009;5:499-521.
20. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F (ab') (2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51:15-24.
21. Tax WJ, Tamboer WP, Jacobs CW, et al. Role of polymorphic Fc receptor Fc gammaRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31). Transplantation. 1997;63:106-112.
22. Szodoray P, Alex P, Dandapani V, et al. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand J Immunol. 2004;60:209-218.